Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
:KURA
KURA Analyst Ratings
Strong Buy
12 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KURA Stock 12 Month Forecast
Average Price Target
$26.25
▲(243.14% Upside)
| Highest Price Target$40.00 | Average Price Target$26.25 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JMP Securities
Reiterated
02/28/25
BTIG
Reiterated
02/27/25
Scotiabank
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
Wedbush
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
Bank of America Securities
Reiterated
02/26/25
TD Cowen
Reiterated
02/26/25
LifeSci Capital
$24
Buy
213.73%
Upside
Reiterated
02/26/25
Kura Oncology's Strategic Advancements and Financial Health Drive Buy Ratings: This aernoon aer market close, KURA provided an update on FY 2024 earnings that included updated guidance on KOMET-017 data melines and disclosed ASCO as the venue for full monotherapy topline data read-out in r/r NPM1m AML. On 1L zio combinaons, KURA ancipates 2028 ming for topline MRD-negave CR results from Ph 3 KOMET-017-IC (Intensive Combinaon) -- an endpoint which could enable accelerated approval in the US for frontline NPM1m and KMT2Ar AML. Both KOMET-017-IC and NIC (Non-Intensive Combinaon) are expected to iniate in 2H 2025. On upcoming full r/r NPM1m monotherapy data, KURA confirmed that the topline dataset has been submied for presentaon at ASCO and will include the same denominator of paents as submied to the FDA. Recall that earlier this month, KURA announced that the trial had succeeded in achieving its primary endpoint, and mgmt suggested ORR fell in the range of 21-29%.
Leerink Partners
$23
Buy
200.65%
Upside
Reiterated
02/26/25
Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)
Mizuho Securities
―
Buy
―
Reiterated
02/26/25
Kura Oncology's Promising Pipeline and Strategic Focus Justify Buy Rating
Jefferies
$28
Buy
266.01%
Upside
Assigned
01/22/25
Kura Oncology (KURA) Gets a Buy from Jefferies
Brookline Capital Markets
$35→$40
Buy
422.88%
Upside
Reiterated
01/06/25
Kura Oncology (KURA) PT Raised to $40 at Brookline Capital MarketsBrookline Capital Markets analyst Leah Rush Cann raised the price target on Kura Oncology (NASDAQ: KURA) to $40.00 (from $35.00) while maintaining a Buy rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JMP Securities
Reiterated
02/28/25
BTIG
Reiterated
02/27/25
Scotiabank
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
Wedbush
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
Bank of America Securities
Reiterated
02/26/25
TD Cowen
Reiterated
02/26/25
LifeSci Capital
$24
Buy
213.73%
Upside
Reiterated
02/26/25
Kura Oncology's Strategic Advancements and Financial Health Drive Buy Ratings: This aernoon aer market close, KURA provided an update on FY 2024 earnings that included updated guidance on KOMET-017 data melines and disclosed ASCO as the venue for full monotherapy topline data read-out in r/r NPM1m AML. On 1L zio combinaons, KURA ancipates 2028 ming for topline MRD-negave CR results from Ph 3 KOMET-017-IC (Intensive Combinaon) -- an endpoint which could enable accelerated approval in the US for frontline NPM1m and KMT2Ar AML. Both KOMET-017-IC and NIC (Non-Intensive Combinaon) are expected to iniate in 2H 2025. On upcoming full r/r NPM1m monotherapy data, KURA confirmed that the topline dataset has been submied for presentaon at ASCO and will include the same denominator of paents as submied to the FDA. Recall that earlier this month, KURA announced that the trial had succeeded in achieving its primary endpoint, and mgmt suggested ORR fell in the range of 21-29%.
Leerink Partners
$23
Buy
200.65%
Upside
Reiterated
02/26/25
Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)
Mizuho Securities
―
Buy
―
Reiterated
02/26/25
Kura Oncology's Promising Pipeline and Strategic Focus Justify Buy Rating
Jefferies
$28
Buy
266.01%
Upside
Assigned
01/22/25
Kura Oncology (KURA) Gets a Buy from Jefferies
Brookline Capital Markets
$35→$40
Buy
422.88%
Upside
Reiterated
01/06/25
Kura Oncology (KURA) PT Raised to $40 at Brookline Capital MarketsBrookline Capital Markets analyst Leah Rush Cann raised the price target on Kura Oncology (NASDAQ: KURA) to $40.00 (from $35.00) while maintaining a Buy rating.
Best Analysts Covering Kura Oncology
Which Analyst Should I Follow If I Want to Buy KURA and Sell After:
1 Month
xxx
Success Rate
12/17 ratings generated profit
Average Return
+0.54%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +0.54% per trade.
3 Months
xxx
Success Rate
25/43 ratings generated profit
Average Return
+11.45%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +11.45% per trade.
1 Year
Success Rate
17/43 ratings generated profit
Average Return
+18.08%
reiterated a buy rating 3 months ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 39.53% of your transactions generating a profit, with an average return of +18.08% per trade.
2 Years
xxx
Success Rate
22/43 ratings generated profit
Average Return
+24.04%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 51.16% of your transactions generating a profit, with an average return of +24.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KURA Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
28
29
31
28
21
Buy
7
7
7
5
3
Hold
7
6
6
7
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
42
44
40
31
Each month's total comprises the sum of three months' worth of ratings.
KURA Financial Forecast
KURA Stock Forecast FAQ
What is KURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kura Oncology’s 12-month average price target is $26.25.
What is KURA’s upside potential, based on the analysts’ average price target?
Kura Oncology has 243.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KURA a Buy, Sell or Hold?
Kura Oncology has a consensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.
What is Kura Oncology’s price target?
The average price target for Kura Oncology is $26.25. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 243.14% Increase from the current price of $7.65.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 243.14% Increase from the current price of $7.65.
What do analysts say about Kura Oncology?
Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of KURA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.